Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...

Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia. The post Women’s Health ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of ...

Management indicated the TakeAim Lymphoma study in PCNSL is on track for full enrollment within 12 to 18 months, with anticipated data and potential regulatory submissions following patient follow-up.